Eli Lilly & Co (LLY) Earnings Date & Reports

Key Takeaways

• Earnings Date: Eli Lilly reports second-quarter 2026 results on Wednesday, August 5, before the market opens, with a conference call to follow at 10:00 a.m. Eastern time.
• Consensus Revenue: Wall Street expects revenue of approximately $20.5 billion, which would represent roughly 32% growth from the $15.6 billion reported in the same quarter a year ago.
• EPS Expectations: Analysts forecast earnings per share (EPS) around $8.81, up significantly from $6.31 in Q2 2025, reflecting continued operating leverage from Lilly's incretin franchise.
• GLP-1 Dominance: Mounjaro and Zepbound are projected to generate roughly $13 billion in combined quarterly revenue, anchoring the investment case heading into the print.
• Guidance in Focus: With the stock trading near $1,149 and commanding a forward price-to-earnings (P/E) ratio above 32, investors are watching whether management raises its full-year 2026 revenue guidance of $82 billion to $85 billion.
• Foundayo Launch: The newly approved oral obesity pill Foundayo (orforglipron), which launched in April, will receive its first full-quarter commercial update, a key swing factor for sentiment.

Earnings Context and Why It Matters

Eli Lilly has become the world's most valuable pharmaceutical company, crossing a market capitalization of roughly $1 trillion, driven almost entirely by the global boom in GLP-1 (glucagon-like peptide-1) receptor agonists for diabetes and obesity. The company's Q1 2026 results set a towering precedent: revenue grew 56% year-over-year to $19.8 billion, and non-GAAP (Generally Accepted Accounting Principles, adjusted) EPS of $8.55 crushed consensus by more than $1.50. With shares up more than 50% over the past 12 months, this Q2 report arrives at a moment when expectations are priced for excellence. A simple beat may not be enough; the market is looking for a guidance raise and tangible evidence that the oral obesity pill Foundayo can broaden Lilly's reach beyond injectable treatments.

Earnings Expectations

Wall Street consensus, tracked across 20 analysts according to Yahoo Finance, projects Q2 2026 revenue of roughly $20.49 billion and EPS of approximately $8.81. Revenue estimates range from $20.08 billion on the low end to $21.2 billion on the high end, while EPS forecasts span $8.16 to $9.36. These figures compare to Q2 2025 actuals of $15.56 billion in revenue and $6.31 in EPS.

Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) remain the dominant earnings engines. In Q1 2026, the combined franchise generated $12.8 billion in global revenue. Analysts expect roughly $13 billion from the two drugs this quarter, representing close to two-thirds of total company sales. Investors will also closely monitor early prescription data for Foundayo, the oral GLP-1 pill that received FDA (U.S. Food and Drug Administration) approval for obesity and launched in April 2026. Early Q1 commentary indicated over 20,000 patients had been treated, with roughly 80% of prescriptions coming from patients new to the GLP-1 class.

Beyond the headline numbers, analysts at Goldman Sachs and Bernstein have flagged the size of any full-year guidance raise as the single most important variable for the stock's reaction. Lilly currently guides to 2026 revenue of $82 billion to $85 billion and non-GAAP EPS of $35.50 to $37.00, both raised by $2 billion and $2.00, respectively, alongside the Q1 report.

AI Screener

As investors prepare for a high-stakes earnings event like Eli Lilly's, tools that streamline market research become especially valuable. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors filter the market using technical patterns, fundamental data, trend signals, volatility metrics, and AI-driven ratings. Users can scan thousands of stocks and ETFs with customizable filters for industry, market capitalization, technical indicators, price patterns, and performance benchmarks. Whether identifying breakout candidates, assessing trending sectors, or narrowing a watchlist ahead of earnings season, the AI Screener offers a faster and more structured approach than manual screening. Explore the screener to uncover trade ideas aligned with your own criteria.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 report is broadly bullish but carries a distinct edge of caution. Of 29 analysts covering LLY, 22 rate the stock a Strong Buy, three a Moderate Buy, and four a Hold, with an average price target near $1,277 — implying roughly 11% upside from the July 31 close of $1,148.84. Guggenheim and Truist both raised price targets ahead of the print, citing accelerating prescription trends and favorable foreign exchange dynamics.

However, the stock pulled back 4.55% on July 30, underscoring the asymmetric risk profile when valuations are stretched. At approximately 33 times forward earnings, LLY trades at a significant premium to the broader pharmaceutical sector. Historical precedent adds context: after Q1 2026 results, the stock surged 9.8% the following day. But in Q2 2025, shares dropped nearly 13% post-earnings despite a broadly solid report, illustrating how high expectations can punish even strong numbers if guidance or nuance disappoints. With the stock up roughly 30% in Q2 alone, the bar for a positive reaction is unusually high.

Forward Outlook and Key Factors to Monitor

Guidance will dominate the post-earnings conversation. Management raised its full-year revenue outlook alongside Q1 results, and the market has already priced in the possibility of a further upward revision. Goldman Sachs models approximately $86.1 billion in 2026 revenue, above the high end of Lilly's current $82 billion to $85 billion range, suggesting any raise below that threshold may be met with a muted response.

Foundayo's early commercial trajectory is a critical second watchpoint. As an oral alternative to injectable GLP-1s, it addresses a substantial unmet need for patients unwilling or unable to take weekly injections. Pharmacy availability, payer coverage, and prescriber breadth will be scrutinized. Early indicators from Q1 pointed to coverage at two of the three largest pharmacy benefit managers (PBMs) and availability on over 12 major telehealth platforms, but the Q2 update will show whether momentum is accelerating or plateauing.

International growth, particularly for Mounjaro in markets such as Japan, Korea, and Europe, is another variable. International incretin sales grew 77% year-over-year in Q1, and continued momentum abroad could offset the low-to-mid-teens pricing headwinds that management has flagged for 2026. Lastly, pipeline updates — including the 42 active Phase III programs, progress on retatrutide, and any new data from the Alzheimer's franchise featuring Kisunla (donanemab) — could influence the long-term growth narrative even if they do not directly affect near-term financials.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations